TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
FTH

Faeth Therapeutics, Inc.

Healthcare · Biotechnology

27.80$ -0.8% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Faeth Therapeutics, Inc. (FTH)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.6% of the shares are freely tradable; institutional investors hold 25.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 25.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 1.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 71.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 26Mio.

Largest Shareholders

Institutions

Institutions FTH
Name Stake (%) Shares Change (%) Date
Vivo Capital, LLC 2.79 722,020 +0.0 06/30/2026
Logos Global Management LP 2.79 722,020 +2,306.7 06/30/2026
Caligan Partners LP 2.44 629,467 +399.6 06/30/2026
Trails Edge Capital Partners, LP 1.99 515,335 +312.3 06/30/2026
Octagon Capital Advisors LP 1.40 361,010 +0.0 06/30/2026
Cormorant Asset Management, LLC 1.19 306,222 +0.0 03/31/2026
StemPoint Capital LP 1.03 265,746 +0.0 03/31/2026

Funds

Funds FTH
Name Stake (%) Shares Change (%) Date
Polar Capital Biotech S Inc 3.82 986,890 +0.0 07/31/2026
Franklin Biotechnology Discv A(acc)USD 1.30 337,086 +7.4 07/31/2026
Franklin Biotechnology Discovery A 0.70 180,711 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?